XNTR 936
Alternative Names: XNTR-936Latest Information Update: 19 May 2021
Price :
$50 *
At a glance
- Originator Xennials Therapeutics
- Class Antineoplastics
- Mechanism of Action Androgen receptor antagonists; Poly(ADP-ribose) polymerase inhibitors; STAT transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 May 2021 XNTR 936 is available for licensing as of 04 May 2021. https://xennialstherapeutics.com/contact-us/
- 04 May 2021 Preclinical trials in Cancer in USA (unspecified route) before May 2021 (Xennials Therapeutics pipeline, May 2021)